Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive ...

Quest Diagnostics Incorporated shows post-pandemic growth with Q3 results, strategic expansion, and steady returns. Click for ...

Quest Diagnostics has seen its Fair Value Estimate rise moderately from $191.56 to $197.25 per share, reflecting a more optimistic outlook among analysts. This upward revision is largely due to strong ...

Laboratory operator Quest Diagnostics raised its full-year forecast for profit and revenue on Tuesday, banking on robust demand for its diagnostic tests, after posting strong results for the third ...

It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

Shares of Quest Diagnostics (NASDAQ: DGX) are falling Tuesday after the medical laboratories company shared mixed earnings ...

Quest Diagnostics (DGX) delivered earnings and revenue surprises of +3.59% and +3.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

The Rising Wave of Esoteric Testing The Esoteric Testing Market represents a specialized segment of diagnostic laboratory services that focuses on rare and complex tests not routinely performed in ...

Strong growth, raised guidance, and new partnerships signal continued momentum amid regulatory and cost headwinds.

Quest Diagnostics Incorporated stock reached an all-time high of 191.87 USD, marking a significant milestone for the company. According to InvestingPro data, the company maintains a "GREAT" financial ...

We came across a bullish thesis on Quest Diagnostics Incorporated on Quality Value Investing’s Substack by David J. Waldron.

Quest Diagnostics raised its profit and revenue outlook for the year after strong organic growth and acquisitions boosted its top and bottom lines in the third quarter. The provider of diagnostic ...